Navigation Links
BMP Sunstone to Host Follow-Up 3Q08 Conference Call Due to Technical Difficulties Encountered on Tuesday's Call
Date:11/11/2008

PLYMOUTH MEETING, Pa., Nov. 11 /Xinhua-PRNewswire-FirstCall/ -- BMP Sunstone Corporation (Nasdaq: BJGP) ("BMP Sunstone" or the "Company"), today announced that due to the technical difficulties encountered on today's conference call, the company will hold a second call tomorrow, Wednesday, November 12, 2008. On this call, BMP Sunstone will give callers the opportunity to ask questions since technical difficulties prevented the Company from addressing all questions on today's call. The transcript of today's call will be posted on the company's website as soon as possible.

Details for Wednesday's Call

The Company will hold a conference call at 9:00 am ET on Wednesday, November 12, 2008. Listeners may access the call by dialing 1-888-713-4214 or 1-617.213.4866 for international callers, access code 93845949. A webcast will also be available through the Company's website at http://www.bmpsunstone.com . A replay of the call will be available through November 19, 2008. Listeners may access the replay by dialing 1-888-286-8010 or 1 617-801-6888 for international callers, access code: 41091128.

About BMP Sunstone Corporation

BMP Sunstone Corporation is a specialty pharmaceutical company that is building a proprietary portfolio of branded pharmaceutical and healthcare products in China. Currently this portfolio includes eight products under exclusive multi-year licenses for China, primarily focused on women's health and pediatrics. The Company also owns Sunstone Pharmaceutical Co. Ltd., which manufactures leading pediatric and women's health products, including two of China's most recognized brands, "Hao Wawa" and "Confort," sold through approximately 50,000 pharmacies in China. The Company also provides pharmaceutical distribution services through its subsidiaries in Beijing and Shanghai, and through its affiliate, Guangzhou Pharmaceuticals Corp. The Company has its main office in Beijing, with a US office in Plymouth Meeting, PA. For more information, please visit http://www.bmpsunstone.com .

Safe Harbor Statement

This news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts, including but not limited to statements about the timing of the completion and terms of the proposed acquisition of 75% of Shengda, the Company's revenue and net income guidance for 2008, the timing of the launch of GoodBaby Multivitamin Granules or any other Company products, use of proceeds from the registered direct offering, the possibility of completing any future acquisitions or receiving profits from Alliance BMP Limited, the ability to successfully integrate the Company's distribution platform, the ability to realize synergies among existing and new Rx and OTC products and channels, future investment in the Company's product portfolio and national leading brands, the focus of the Company on revenue growth and market penetration of the Company's current products, expansion of the Company's product portfolio at BMP China, and solidification of Sunstone's market leader position. These statements are subject to uncertainties and risks including, but not limited to, negotiating definitive terms and definitive agreements regarding the proposed acquisition, satisfying the conditions in such definitive agreements, regulatory review, sales and marketing, operating performance, general financial, economic, and political conditions affecting the biotechnology and pharmaceutical industries and the Chinese pharmaceutical market, the ability to timely manufacture and distribute the Company's products, the need to use cash for unexpected reasons, the results of Alliance BMP Limited operations are less than expected or Alliance BMP Limited decides not to make a distribution of profits to its equityholders, and other risks contained in reports filed by the Company with the Securities and Exchange Commission. In addition, the Company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.


'/>"/>
SOURCE BMP Sunstone Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. BMP Sunstone Reports Third Quarter 2008 Financial Results
2. BMP Sunstone Announces Participation in November Investor Conferences
3. BMP Sunstone Announces Participation in September Investor Conference
4. BMP Sunstone Receives Production License from the SFDA to Manufacture and Market Pediatric Multivitamin Granules in the PRC
5. BMP Sunstone Reports Second Quarter 2008 Financial Results
6. BMP Sunstone Corporation Appoints Zhiqiang Han to President and Chief Operating Officer
7. BMP Sunstone Receives Import Drug License (IDL) from SFDA
8. BMP Sunstone Receives SFDA Acceptance for Enablex(R) Clinical Trial
9. Follow-up Phone Surveys: Effective Customer Service Assessment Tool for Improving Satisfaction
10. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
11. Kendle to Present at the 2008 Credit Suisse Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... DuPont Pioneer and ... they have entered into a multiyear collaboration to identify and characterize novel CRISPR-Cas ... tools for gene editing across all applications. , Under the terms of the ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... the pharmaceutical and biotechnology industries to improve patient outcomes and quality of life, ... in analytical testing are being attributed to new regulatory requirements for all new ...
(Date:10/11/2017)... ... October 11, 2017 , ... ... its endogenous context, enabling overexpression experiments and avoiding the use of exogenous expression ... guides is transformative for performing systematic gain-of-function studies. , This complement to ...
(Date:10/11/2017)... ... October 11, 2017 , ... Proscia Inc ., ... a Webinar titled, “Pathology is going digital. Is your lab ready?” with Dr. ... best practices and how Proscia improves lab economics and realizes an increase in ...
Breaking Biology Technology:
(Date:10/4/2017)... a global clinical research organization (CRO), announces the launch of Shadow, ... 2017. Shadow is designed to assist medical writers and biometrics teams ... European Medicines Agency (EMA) in meeting the requirements for de-identifying clinical ... ... Tom ...
(Date:7/20/2017)... WASHINGTON , July 20, 2017 Delta (NYSE: ... to board any Delta aircraft at Reagan Washington National Airport (DCA). ... Delta launches biometrics ... Delta,s ... Delta Sky Club is now integrated into the boarding process to ...
(Date:6/14/2017)... PARIS , June 15, 2017  IBM (NYSE: IBM ... the international tech event dedicated to developing collaboration between startups ... on June 15-17. During the event, nine startups will ... deliver value in various industries. ... in the international market, with a 30 percent increase in ...
Breaking Biology News(10 mins):